Literature DB >> 25769714

Regional therapies for in-transit disease.

Paul J Speicher1, Claire H Meriwether1, Douglas S Tyler2.   

Abstract

In-transit melanoma is an uncommon pattern of recurrence, but presents unique management challenges and opportunities for treatment. The clinical presentation usually involves from 1 to more than 100 small subcutaneous or cutaneous nodules, ranging from submillimeter to multiple centimeters in diameter. Regional chemotherapy techniques are a mainstay of treatment of patients without systemic disease spread. Future applications of regional therapy are likely to involve combination therapy with cytotoxic agents and novel immune modulators. Regional therapy provides distinct opportunities for the treatment of unresectable disease, and offers a unique platform for investigation of novel therapeutics in early-stage clinical trials. Published by Elsevier Inc.

Entities:  

Keywords:  In-transit melanoma; Isolated limb infusion; Isolated limb perfusion; Regional therapy

Mesh：

Substances：

Year:  2015        PMID： 25769714      PMCID： PMC5161093          DOI： 10.1016/j.soc.2014.12.008

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  60 in total

1.  Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit.

Authors:  O CREECH; E T KREMENTZ; R F RYAN; J N WINBLAD
Journal:  Ann Surg       Date:  1958-10       Impact factor: 12.969

2.  Combined administration of aureomycin and nitrogen mustard. II. Effects of the intra-arterial administration on human cancer.

Authors:  R BARBERIO; N BERRY; J BATEMAN; J K CROMER; C T KLOPP
Journal:  Cancer       Date:  1953-03       Impact factor: 6.860

3.  Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy.

Authors:  D W Siemann; M Chapman; A Beikirch
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-02       Impact factor: 7.038

4.  Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.

Authors:  Michelle Hong; Anne-Laure Puaux; Caleb Huang; Laure Loumagne; Charlene Tow; Charles Mackay; Masashi Kato; Armelle Prévost-Blondel; Marie-Françoise Avril; Alessandra Nardin; Jean-Pierre Abastado
Journal:  Cancer Res       Date:  2011-09-26       Impact factor: 12.701

5.  Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion.

Authors:  F Di Filippo; A Calabrò; D Giannarelli; S Carlini; F Cavaliere; F Moscarelli; R Cavaliere
Journal:  Cancer       Date:  1989-06-15       Impact factor: 6.860

6.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

7.  Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma.

Authors:  John C Kang; Leslie A Wanek; Richard Essner; Mark B Faries; Leland J Foshag; Donald L Morton
Journal:  J Clin Oncol       Date:  2005-07-20       Impact factor: 44.544

8.  Prognostic parameters in recurrent malignant melanoma.

Authors:  C P Karakousis; D F Temple; R Moore; J L Ambrus
Journal:  Cancer       Date:  1983-08-01       Impact factor: 6.860

9.  Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.

Authors:  D L Fraker; H R Alexander; M Andrich; S A Rosenberg
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

10.  Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology.

Authors:  Amira Sanki; Peter C A Kam; John F Thompson
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969
View more
  3 in total

1.  Correlates of response and outcomes with talimogene laherperpvec.

Authors:  Alice Y Zhou; Daniel Y Wang; Svetlana McKee; Fei Ye; Chun-Che Wen; Debbie E Wallace; Kristin K Ancell; Robert M Conry; Douglas B Johnson
Journal:  J Surg Oncol       Date:  2019-07-02       Impact factor: 3.454

Review 2.  In-transit metastatic cutaneous melanoma: current management and future directions.

Authors:  Ayushi Patel; Michael J Carr; James Sun; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2021-05-17       Impact factor: 5.150

3.  Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases.

Authors:  Anna K Lawless; David J Coker; Serigne N Lo; Tasnia Ahmed; Richard A Scolyer; Sydney Ch'ng; Omgo E Nieweg; Kerwin Shannon; Andrew Spillane; Jonathan R Stretch; John F Thompson; Robyn P M Saw
Journal:  Ann Surg Oncol       Date:  2022-06-30       Impact factor: 4.339
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.